Univariable analysis of factors predictive for OS.
Characteristic | All |
Transplanted |
|||||
---|---|---|---|---|---|---|---|
3-year OS (%) | 3-year OS (%) | ||||||
Age group | |||||||
AYA | 39.0 | 0.064 | 52.9 | 0.690 | |||
Adult and elderly | 19.6 | 55.0 | |||||
Sex | |||||||
Male | 33.6 | 0.876 | 54.2 | 0.906 | |||
Female | 26.8 | 52.9 | |||||
WCC at diagnosis | |||||||
>30×109/L | 25.5 | 0.585 | 52.3 | 0.684 | |||
<30×109/L | 35.9 | 63.6 | |||||
MRD status (%) | ≥0.1 | <0.1 | ≥0.1 | <0.1 | |||
TP1 | 36.7 | 36.1 | 0.974 | ||||
TP2 | 23.5 | 53.1 | 0.077 | ||||
TP3 | 11.5 | 65.4 | 0.005 | 25.0 | 73.9 | 0.003 | |
Chemotherapy | |||||||
GMALL/BFM | 25.7 | 0.081 | |||||
Hyper-CVAD | 33.7 | ||||||
TKI | |||||||
Yes (2012–2018) | 33.7 | 0.390 | |||||
No (2006–2011) | 23.5 | ||||||
Transplant | |||||||
Yes | 58.9 | <0.001 | |||||
No | 10.6 | ||||||
Disease status at transplant | |||||||
CR1 | 65.9 | 0.003 | |||||
CR>1 | 16.7 |
Significant
Abbreviations: ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; CR, complete remission; MRD, measurable residual disease; OS, overall survival; TKI, tyrosine kinase inhibitor; TP1, timepoint 1; TP2, timepoint 2; TP3, timepoint 3; WCC, white cell count.